<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335136</url>
  </required_header>
  <id_info>
    <org_study_id>APN01-01-COVID19</org_study_id>
    <nct_id>NCT04335136</nct_id>
  </id_info>
  <brief_title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</brief_title>
  <acronym>APN01-COVID-19</acronym>
  <official_title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apeiron Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apeiron Biologics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant human angotensin-converting enzyme 2 (rhACE2) as a treatment for patients with&#xD;
      COVID-19 to block viral entry and decrease viral replication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Actual">December 26, 2020</completion_date>
  <primary_completion_date type="Actual">December 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause-death or Invasive Mechanical Ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>The primary endpoint was a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate Dehydrogenase (LDH) Level</measure>
    <time_frame>Day 5</time_frame>
    <description>Log transformed levels of LDH at Day 5 as a surrogate marker for organ damage (powered secondary endpoint).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28-day mortality (all cause-death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days (VFD)</measure>
    <time_frame>28 days</time_frame>
    <description>VFD up to 28 days or hospital discharge. VFD and mechanical-VFD (mVFD) were calculated as time in the study minus duration of ventilation and were set to zero if the duration of ventilation exceeded the time in the study.&#xD;
Three analysis approaches were used: 1) Death not censored: (m)VFD was set to zero for patients who died. 2) Death censored: patients who died before or on Day 28 were censored at the day before death. 3) Alive patients analyzed: only patients who were alive at Day 28, hospital discharge, or early termination were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>28 days</time_frame>
    <description>Time to death (all causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Responders, Defined as ≥2 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28</measure>
    <time_frame>Day 7, Day 10, Day 14, Day 28</time_frame>
    <description>The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral deoxyribonucleic acid (DNA) detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, partial pressure of oxygen (pO2)/fraction of inspired oxygen (FiO2)≥ 150 or oxygen saturation (SpO2)/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The number of days from randomization to discharge from hospital was calculated (Kaplan-Meier analysis).&#xD;
Patients without hospitalization or without documented hospital discharge who completed the study or were early terminated before Day 28 were censored at the date of study completion or discontinuation, respectively.&#xD;
Patients who died before Day 28 were censored at the date of death even if early terminated before.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Ribonucleic Acid (RNA).</measure>
    <time_frame>Day 1, Day 3, Day 5, Day 7, Day 14, and Day 28/End of study (EOS)</time_frame>
    <description>Viral RNA was assessed in blood samples using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and projected to RNA copies per mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-point Decrease in WHO's 11-Point Score System</measure>
    <time_frame>Up to 28 days.</time_frame>
    <description>The time from randomization to an at least 2-point decrease in the WHO scale was calculated. The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral DNA detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, pO2/FiO2 ≥ 150 or SpO2/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or ECMO = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement in disease status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The number of patients receiving mechanical ventilation and supplemental oxygen was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time from randomization to first use of invasive mechanical ventilation was calculated (Kaplan-Meier analysis).&#xD;
Patients without documented invasive mechanical ventilation who completed the study, were early terminated or discharged from hospital before Day 28 were censored at the date of study completion, discontinuation or discharge from hospital, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 Value</measure>
    <time_frame>Day 1, Day 7, Day 10, Day 14, and Day 28</time_frame>
    <description>The ratio in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) was assessed by analysis of patient's blood gas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)</measure>
    <time_frame>Day -1 (Screening), Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
    <description>The mSOFA score predicts intensive care unit mortality using clinical and laboratory variables. 5 organ systems (respiratory SpO2/FiO2; liver; cardiovascular/hypotension; Central nervous System/Glasgow Coma Score; renal/creatinine), all, except for liver, scored on a 0 to 4 scale (liver: 2-point scale: 0 or 3) according to specified criteria indicating severity, with the total score ranging from 0 to a maximum score of 19. A higher score reflects a worse disease state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Count</measure>
    <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
    <description>Lymphocytes were assessed in blood samples from the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein Levels</measure>
    <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
    <description>C-reactive protein was assessed in blood samples from the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer</measure>
    <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
    <description>D-Dimer was assessed in blood samples from the patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log-transformed Levels of LDH</measure>
    <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
    <description>Log transformed levels of LDH in blood were assessed as a surrogate marker for organ damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group A (active) APN01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (placebo control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RhACE2 APN01</intervention_name>
    <description>Patients will be treated with APN01 intravenously twice daily (BID).</description>
    <arm_group_label>Group A (active) APN01</arm_group_label>
    <other_name>APN01</other_name>
    <other_name>Recombinant human angiotensin-converting enzyme 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological saline solution</intervention_name>
    <description>Patients will be treated with placebo intravenously twice daily (BID).</description>
    <arm_group_label>Group B (placebo control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized male or female&#xD;
&#xD;
          2. Diagnosed to be COVID-19 POSITIV&#xD;
&#xD;
          3. Signed Inform Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any patient whose clinical condition is deteriorating rapidly&#xD;
&#xD;
          2. Known history of positive Hepatitis B surface antigen, Hepatitis C antibody or HIV&#xD;
             antibody&#xD;
&#xD;
          3. History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or Medical&#xD;
             Monitor, contraindicates their participation&#xD;
&#xD;
          4. Pregnant females as determined by positive serum or urine hCG test prior to dosing&#xD;
&#xD;
          5. Lung transplantation&#xD;
&#xD;
          6. Pre-existing renal failure, i.e. requiring renal replacement therapy with hemodialysis&#xD;
             or peritoneal dialysis&#xD;
&#xD;
          7. There are other uncontrolled co-morbidities that increase the risks associated with&#xD;
             the study drug administration, that are assessed by the medical expert team as&#xD;
             unsuitable&#xD;
&#xD;
          8. Patient in clinical trials for COVID-19 within 30 days before ICF&#xD;
&#xD;
          9. Immunocompromised patients (chemotherapy, HIV, organ transplants, stem cell&#xD;
             transplants)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bundgaard, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cap. Region's Unit of Inherited Cardiac Diseases, Faculty Health&amp;Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Educational Institution &quot;Clinical Hospital № 5, Barnaul&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;State Clinical Hspital № 15 named after O.M. Filatov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Budgetary Healthcare Institution &quot;City Clinical Hospital №52 of Health Department of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Budgetary Healthcare Institution &quot;N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg SBHI City Hospital 38 named after N A Semashko</name>
      <address>
        <city>Pushkin</city>
        <zip>196600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Ryazan State Medical University named after I.P. Pavlov&quot; HD RF</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandrovskaya Hospital</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budget Healthcare Institution City Hospital 15</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot; Saratov State Medical University named after V.I. Razumovsky&quot; HD RF</name>
      <address>
        <city>Saratov</city>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Healthcare Institution &quot;Clinical Hospital №1&quot;</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary institution of Healthcare of Tver region &quot;Regional clinical hospital&quot;</name>
      <address>
        <city>Tver</city>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems &quot;Healthy Ageing&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust/University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <results_first_submitted>June 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2021</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04335136/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04335136/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>185 Patients were screened of whom 181 patients were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A (Active) APN01</title>
          <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
        </group>
        <group group_id="P2">
          <title>Group B (Placebo Control)</title>
          <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Health-threatening condition</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Erroneously randomized</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients who received at least 1 dose of investigational medicinal product (IMP).</population>
      <group_list>
        <group group_id="B1">
          <title>Group A (Active) APN01</title>
          <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
        </group>
        <group group_id="B2">
          <title>Group B (Placebo Control)</title>
          <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="11.3"/>
                    <measurement group_id="B2" value="58.5" spread="12.4"/>
                    <measurement group_id="B3" value="59.0" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Data of 1 patient in the placebo group are missing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="88"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause-death or Invasive Mechanical Ventilation</title>
        <description>The primary endpoint was a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.</description>
        <time_frame>28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of investigational medicinal product (IMP).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause-death or Invasive Mechanical Ventilation</title>
          <description>The primary endpoint was a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.</description>
          <population>All randomized patients who had received at least 1 dose of investigational medicinal product (IMP).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis tested: H0: pAPN01 = pPlacebo; H1: pAPN01 ≠ pPlacebo (with p=proportion of patients with event).&#xD;
A total of 186 patients (93 per group) was estimated to yield 80% power to detect a 20% absolute risk reduction in the primary, from 50% in the placebo group to 30% in the APN01 group, at a 2-sided alpha of 0.05. To consider patients who would be randomized but not treated, a total of 200 patients (100 per group) were planned to be enrolled.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5207</p_value>
            <p_value_desc>The level of significance was 5% (2-sided).</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3588</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Degree of freedom: 1</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lactate Dehydrogenase (LDH) Level</title>
        <description>Log transformed levels of LDH at Day 5 as a surrogate marker for organ damage (powered secondary endpoint).</description>
        <time_frame>Day 5</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and had an LDH measurement at Day 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Lactate Dehydrogenase (LDH) Level</title>
          <description>Log transformed levels of LDH at Day 5 as a surrogate marker for organ damage (powered secondary endpoint).</description>
          <population>All randomized patients who had received at least 1 dose of IMP and had an LDH measurement at Day 5.</population>
          <units>Log U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="0.470"/>
                    <measurement group_id="O2" value="5.80" spread="0.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>28-day mortality (all cause-death).</description>
        <time_frame>28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>28-day mortality (all cause-death).</description>
          <population>All randomized patients who had received at least 1 dose of IMP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days (VFD)</title>
        <description>VFD up to 28 days or hospital discharge. VFD and mechanical-VFD (mVFD) were calculated as time in the study minus duration of ventilation and were set to zero if the duration of ventilation exceeded the time in the study.&#xD;
Three analysis approaches were used: 1) Death not censored: (m)VFD was set to zero for patients who died. 2) Death censored: patients who died before or on Day 28 were censored at the day before death. 3) Alive patients analyzed: only patients who were alive at Day 28, hospital discharge, or early termination were included in the analysis.</description>
        <time_frame>28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP. In addition, a subgroup analysis was performed including only patients who were still alive at Day 28 (or discharged from the hospital/early terminated).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days (VFD)</title>
          <description>VFD up to 28 days or hospital discharge. VFD and mechanical-VFD (mVFD) were calculated as time in the study minus duration of ventilation and were set to zero if the duration of ventilation exceeded the time in the study.&#xD;
Three analysis approaches were used: 1) Death not censored: (m)VFD was set to zero for patients who died. 2) Death censored: patients who died before or on Day 28 were censored at the day before death. 3) Alive patients analyzed: only patients who were alive at Day 28, hospital discharge, or early termination were included in the analysis.</description>
          <population>All randomized patients who had received at least 1 dose of IMP. In addition, a subgroup analysis was performed including only patients who were still alive at Day 28 (or discharged from the hospital/early terminated).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VFD (death not censored)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="8.8"/>
                    <measurement group_id="O2" value="16.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VFD (death censored)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="8.6"/>
                    <measurement group_id="O2" value="16.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VFD (subgroup: alive patients)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="84"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="7.3"/>
                    <measurement group_id="O2" value="17.9" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mVFD (death not censored)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="8.4"/>
                    <measurement group_id="O2" value="25.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mVFD (death censored)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="6.6"/>
                    <measurement group_id="O2" value="25.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mVFD (subgroup: alive patients)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="1.9"/>
                    <measurement group_id="O2" value="26.9" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death</title>
        <description>Time to death (all causes).</description>
        <time_frame>28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death</title>
          <description>Time to death (all causes).</description>
          <population>All randomized patients who had received at least 1 dose of IMP.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="6" upper_limit="22">Median time to death could not be estimated due to an insufficient number of patients with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="2" upper_limit="28">Median time to death could not be estimated due to an insufficient number of patients with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Responders, Defined as ≥2 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28</title>
        <description>The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral deoxyribonucleic acid (DNA) detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, partial pressure of oxygen (pO2)/fraction of inspired oxygen (FiO2)≥ 150 or oxygen saturation (SpO2)/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement.</description>
        <time_frame>Day 7, Day 10, Day 14, Day 28</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of the WHO 11-Point Score System at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders, Defined as ≥2 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28</title>
          <description>The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral deoxyribonucleic acid (DNA) detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, partial pressure of oxygen (pO2)/fraction of inspired oxygen (FiO2)≥ 150 or oxygen saturation (SpO2)/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of the WHO 11-Point Score System at the respective timepoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge</title>
        <description>The number of days from randomization to discharge from hospital was calculated (Kaplan-Meier analysis).&#xD;
Patients without hospitalization or without documented hospital discharge who completed the study or were early terminated before Day 28 were censored at the date of study completion or discontinuation, respectively.&#xD;
Patients who died before Day 28 were censored at the date of death even if early terminated before.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge</title>
          <description>The number of days from randomization to discharge from hospital was calculated (Kaplan-Meier analysis).&#xD;
Patients without hospitalization or without documented hospital discharge who completed the study or were early terminated before Day 28 were censored at the date of study completion or discontinuation, respectively.&#xD;
Patients who died before Day 28 were censored at the date of death even if early terminated before.</description>
          <population>All patients who had received at least 1 dose of IMP.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="15"/>
                    <measurement group_id="O2" value="14" lower_limit="13" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Ribonucleic Acid (RNA).</title>
        <description>Viral RNA was assessed in blood samples using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and projected to RNA copies per mL.</description>
        <time_frame>Day 1, Day 3, Day 5, Day 7, Day 14, and Day 28/End of study (EOS)</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of viral RNA at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Ribonucleic Acid (RNA).</title>
          <description>Viral RNA was assessed in blood samples using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and projected to RNA copies per mL.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of viral RNA at the respective timepoint.</population>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27996" spread="78877"/>
                    <measurement group_id="O2" value="3900" spread="5848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20931" spread="53182"/>
                    <measurement group_id="O2" value="13681" spread="45287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9825" spread="32979"/>
                    <measurement group_id="O2" value="11912" spread="75457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5229" spread="24514"/>
                    <measurement group_id="O2" value="2094" spread="8742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9274" spread="78304"/>
                    <measurement group_id="O2" value="53" spread="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to a 2-point Decrease in WHO's 11-Point Score System</title>
        <description>The time from randomization to an at least 2-point decrease in the WHO scale was calculated. The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral DNA detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, pO2/FiO2 ≥ 150 or SpO2/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or ECMO = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement in disease status.</description>
        <time_frame>Up to 28 days.</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to a 2-point Decrease in WHO's 11-Point Score System</title>
          <description>The time from randomization to an at least 2-point decrease in the WHO scale was calculated. The WHO Clinical Progression Scale provides a measure of illness severity across an 11 point range from 0 (not infected) to 10 (dead) as follows (scores 4-9 contain measures of respiratory failure):&#xD;
Uninfected, no viral DNA detected = 0;&#xD;
Asymptomatic, viral DNA detected = 1;&#xD;
Symptomatic, independent = 2;&#xD;
Symptomatic, assistance needed = 3;&#xD;
Hospitalized, no oxygen therapy = 4;&#xD;
Hospitalized, oxygen by mask or nasal prongs = 5;&#xD;
Hospitalized, oxygen by non-invasive ventilation (NIV) or high flow = 6;&#xD;
Intubation and mechanical ventilation, pO2/FiO2 ≥ 150 or SpO2/FiO2≥200 = 7;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 (SpO2/FiO2 &lt; 200) or vasopressors = 8;&#xD;
Mechanical ventilation, pO2/FiO2 &lt; 150 and vasopressors, dialysis, or ECMO = 9;&#xD;
Dead = 10.&#xD;
A decrease in the score reflects an improvement in disease status.</description>
          <population>All randomized patients who had received at least 1 dose of IMP.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="14" upper_limit="27"/>
                    <measurement group_id="O2" value="27" lower_limit="17" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</title>
        <description>The number of patients receiving mechanical ventilation and supplemental oxygen was evaluated.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</title>
          <description>The number of patients receiving mechanical ventilation and supplemental oxygen was evaluated.</description>
          <population>All randomized patients who had received at least 1 dose of IMP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mechanical ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical ventilation and oxygen supplementation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</title>
        <description>Time from randomization to first use of invasive mechanical ventilation was calculated (Kaplan-Meier analysis).&#xD;
Patients without documented invasive mechanical ventilation who completed the study, were early terminated or discharged from hospital before Day 28 were censored at the date of study completion, discontinuation or discharge from hospital, respectively.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge</title>
          <description>Time from randomization to first use of invasive mechanical ventilation was calculated (Kaplan-Meier analysis).&#xD;
Patients without documented invasive mechanical ventilation who completed the study, were early terminated or discharged from hospital before Day 28 were censored at the date of study completion, discontinuation or discharge from hospital, respectively.</description>
          <population>All randomized patients who had received at least 1 dose of IMP.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="0" upper_limit="14">Median time to first invasive mechanical ventilation could not be estimated due to an insufficient number of patients with events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="20">Median time to first invasive mechanical ventilation could not be estimated due to an insufficient number of patients with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PaO2/FiO2 Value</title>
        <description>The ratio in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) was assessed by analysis of patient's blood gas.</description>
        <time_frame>Day 1, Day 7, Day 10, Day 14, and Day 28</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of PaO2/FiO2 at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>PaO2/FiO2 Value</title>
          <description>The ratio in partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) was assessed by analysis of patient's blood gas.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of PaO2/FiO2 at the respective timepoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.07" spread="99.70"/>
                    <measurement group_id="O2" value="185.14" spread="79.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.74" spread="91.66"/>
                    <measurement group_id="O2" value="192.21" spread="92.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.00" spread="204.70"/>
                    <measurement group_id="O2" value="186.62" spread="87.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197.00" spread="99.42"/>
                    <measurement group_id="O2" value="185.00" spread="67.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.00" spread="NA">Data of only 1 patient were available.</measurement>
                    <measurement group_id="O2" value="185.00" spread="116.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)</title>
        <description>The mSOFA score predicts intensive care unit mortality using clinical and laboratory variables. 5 organ systems (respiratory SpO2/FiO2; liver; cardiovascular/hypotension; Central nervous System/Glasgow Coma Score; renal/creatinine), all, except for liver, scored on a 0 to 4 scale (liver: 2-point scale: 0 or 3) according to specified criteria indicating severity, with the total score ranging from 0 to a maximum score of 19. A higher score reflects a worse disease state.</description>
        <time_frame>Day -1 (Screening), Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of the mSOFA score at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)</title>
          <description>The mSOFA score predicts intensive care unit mortality using clinical and laboratory variables. 5 organ systems (respiratory SpO2/FiO2; liver; cardiovascular/hypotension; Central nervous System/Glasgow Coma Score; renal/creatinine), all, except for liver, scored on a 0 to 4 scale (liver: 2-point scale: 0 or 3) according to specified criteria indicating severity, with the total score ranging from 0 to a maximum score of 19. A higher score reflects a worse disease state.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of the mSOFA score at the respective timepoint.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.2"/>
                    <measurement group_id="O2" value="2.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.5"/>
                    <measurement group_id="O2" value="1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.7"/>
                    <measurement group_id="O2" value="1.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.4"/>
                    <measurement group_id="O2" value="0.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocyte Count</title>
        <description>Lymphocytes were assessed in blood samples from the patients.</description>
        <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of lymphocyte count at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocyte Count</title>
          <description>Lymphocytes were assessed in blood samples from the patients.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a measurement of lymphocyte count at the respective timepoint.</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.694"/>
                    <measurement group_id="O2" value="1.06" spread="0.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.843"/>
                    <measurement group_id="O2" value="1.16" spread="0.662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.948"/>
                    <measurement group_id="O2" value="1.62" spread="0.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="1.444"/>
                    <measurement group_id="O2" value="1.79" spread="0.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.773"/>
                    <measurement group_id="O2" value="1.71" spread="0.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="3.420"/>
                    <measurement group_id="O2" value="1.72" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein Levels</title>
        <description>C-reactive protein was assessed in blood samples from the patients.</description>
        <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a C-reactive protein measurement at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein Levels</title>
          <description>C-reactive protein was assessed in blood samples from the patients.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a C-reactive protein measurement at the respective timepoint.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" spread="64.53"/>
                    <measurement group_id="O2" value="62.8" spread="51.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="53.75"/>
                    <measurement group_id="O2" value="43.7" spread="45.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" spread="41.58"/>
                    <measurement group_id="O2" value="26.1" spread="38.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="24.24"/>
                    <measurement group_id="O2" value="26.3" spread="48.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="29.66"/>
                    <measurement group_id="O2" value="38.3" spread="133.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="5.69"/>
                    <measurement group_id="O2" value="8.5" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-Dimer</title>
        <description>D-Dimer was assessed in blood samples from the patients.</description>
        <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had a D-Dimer measurement at the respective timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>D-Dimer</title>
          <description>D-Dimer was assessed in blood samples from the patients.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had a D-Dimer measurement at the respective timepoint.</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1341" spread="2757"/>
                    <measurement group_id="O2" value="1187" spread="3994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1109" spread="1316"/>
                    <measurement group_id="O2" value="881" spread="959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1208" spread="1485"/>
                    <measurement group_id="O2" value="1139" spread="1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="988" spread="1135"/>
                    <measurement group_id="O2" value="1219" spread="2228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1015" spread="1520"/>
                    <measurement group_id="O2" value="1013" spread="2243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573" spread="629"/>
                    <measurement group_id="O2" value="685" spread="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log-transformed Levels of LDH</title>
        <description>Log transformed levels of LDH in blood were assessed as a surrogate marker for organ damage.</description>
        <time_frame>Day -1, Day 3, Day 7, Day 10, Day 14, Day 28/End of study</time_frame>
        <population>All randomized patients who had received at least 1 dose of IMP and who had an LDH measurement at the respective timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Active) APN01</title>
            <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
          </group>
          <group group_id="O2">
            <title>Group B (Placebo Control)</title>
            <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
          </group>
        </group_list>
        <measure>
          <title>Log-transformed Levels of LDH</title>
          <description>Log transformed levels of LDH in blood were assessed as a surrogate marker for organ damage.</description>
          <population>All randomized patients who had received at least 1 dose of IMP and who had an LDH measurement at the respective timepoints.</population>
          <units>Log U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day -1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91" spread="0.442"/>
                    <measurement group_id="O2" value="5.87" spread="0.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.86" spread="0.440"/>
                    <measurement group_id="O2" value="5.88" spread="0.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.77" spread="0.459"/>
                    <measurement group_id="O2" value="5.75" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="0.464"/>
                    <measurement group_id="O2" value="5.67" spread="0.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" spread="0.467"/>
                    <measurement group_id="O2" value="5.52" spread="0.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="0.305"/>
                    <measurement group_id="O2" value="5.50" spread="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A (Active) APN01</title>
          <description>Patients were treated with APN01 (Recombinant human angiotensin-converting enzyme 2 [rhACE2]) intravenously twice daily (BID).</description>
        </group>
        <group group_id="E2">
          <title>Group B (Placebo Control)</title>
          <description>Patients were treated with placebo (physiological saline solution) intravenously twice daily (BID).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Romana Gugenberger</name_or_title>
      <organization>APEIRON Biologics AG</organization>
      <phone>+4366488506236</phone>
      <email>romana.gugenberger@apeiron-biologics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

